Methadone containing products used for opioid use disorder (Q20-20)

Methadone containing products used for opioid use disorder (Q20-20)

Q20-20

Overview

Background
  • Methadone is used for the treatment of opioid use disorder.
  • In 2014/2015, most Canadian public drug plans transitioned from the existing 1mg/ml pharmacist-compounded formulation to Methadone 10 mg/ml, a more stable pre-mixed formulation. Subsequent to this policy change, there has been reports that some patients may experience decreased effectiveness with the newer methadone formulation.
  • There is a need to better understand whether switching from one methadone-containing to another is associated with changes in measures of drug effectiveness or safety.
Aims of the study
  • The study objective is to determine the proportion of patients who experience safety outcomes when switching from compounded methadone, Methadose or Metadol-D to another formulation or brand, and the short-term outcomes in these patients.

Manuscripts

Presentations

Project Team

Site Investigator
Amani Hamad MSc, PhD
Manitoba
Site Investigator
Lauren Bresee PhD
Alberta
Site Investigator
Anat Fisher MD, PhD
British Columbia
Site Investigator
Michael Paterson MSc
Ontario
Analyst
Richard Morrow Ma, PhD Candidate
British Columbia
Analyst
Matthew Dahl BSc
Manitoba
Analyst
Jianguo (James) Zhang MSc
Alberta